MARKET

CLDX

CLDX

Celldex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.30
+0.10
+0.98%
After Hours: 10.15 -0.15 -1.46% 16:00 08/13 EDT
OPEN
10.26
PREV CLOSE
10.20
HIGH
10.41
LOW
10.18
VOLUME
424.87K
TURNOVER
--
52 WEEK HIGH
13.91
52 WEEK LOW
1.500
MARKET CAP
403.00M
P/E (TTM)
-3.4905
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLDX stock price target is 17.00 with a high estimate of 18.00 and a low estimate of 16.00.

EPS

CLDX News

More
Celldex Provides Corporate Update and Reports Second Quarter 2020 Results
\--Conference Call and Webcast today at 4:30pm ET--HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company will host a co
GlobeNewswire · 08/06 20:01
Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call
HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Celldex executives will host a conference call at 4:
GlobeNewswire · 08/03 12:01
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24
Top Ranked Momentum Stocks to Buy for July 9th
Zacks · 07/09 16:01
Celldex Therapeutics, Inc. (CLDX) Shares March Higher, Can It Continue?
Zacks · 07/08 12:32
3 Healthcare Stocks That Surged Last Week
MotleyFool.com · 06/21 12:47
Here's Why Celldex Therapeutics Stock Is Soaring Today
MotleyFool.com · 06/19 04:00

Industry

Biotechnology & Medical Research
+1.09%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About CLDX

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
More

Webull offers kinds of Celldex Therapeutics, Inc. stock information, including NASDAQ:CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.